View Older Stories
-
Wells Fargo Upgrades United Therapeutics Corp. (UTHR) to Overweight
-
BTIG on United Therapeutics Corp. (UTHR): 'We believe Yutrepia likely sees positive readthrough from this data'
-
United Therapeutics (UTHR) Misses Q1 EPS by 117c
-
MannKind develops dry powder inhaler for pulmonary hypertension treatment
-
United Therapeutics presents study data at transplant conference
-
Increasing unusual option volume: UTHR KIE VSAT CP KBWB CM HUN ORBS BZAI CENX
-
Raymond James Starts United Therapeutics Corp. (UTHR) at Outperform
-
United Therapeutics receives FDA regenerative medicine designation for liver device
-
United Therapeutics Corp. (UTHR) PT Raised to $660 at H.C. Wainwright
-
United Therapeutics (UTHR) call put ratio 3.4 calls to 1 put as share price up 12.5%
-
United Therapeutics Corp. (UTHR) PT Raised to $626 at BofA Securities
-
United Therapeutics Corp. (UTHR) PT Raised to $733 at Jefferies
-
United Therapeutics Corp. (UTHR) PT Raised to $733 at Jefferies
-
United Therapeutics Corp. (UTHR) PT Raised to $660 at TD Cowen, 'remains a top pick'
-
Morgan Stanley on United Therapeutics Corp. (UTHR): project Tyvaso '2030/2035 risk-adjusted sales in IPF of $1.2bn/$2.5bn'
-
Jefferies on United Therapeutics Corp. (UTHR): expecting '+15–25%' move following positive topline data
-
United Therapeutics TETON-1 study meets primary endpoint for lung disease treatment
-
United Therapeutics Corp. (UTHR) PT Raised to $625 at Cantor Fitzgerald on IPF Potential
-
TD Cowen on United Therapeutics Corp. (UTHR) Buyback: 'We believe that this signals management's confidence'
-
United Therapeutics Corp. (UTHR) PT Raised to $705 at UBS
-
United Therapeutics Corp. (UTHR) PT Raised to $705 at UBS
-
United Therapeutics Corp. (UTHR) PT Raised to $705 at UBS
-
TD Cowen on United Therapeutics (UTHR): Management Sees Blockbuster Potential as Ralinepag Succeeds
-
United Therapeutics Corp. (UTHR) PT Raised to $668 at Jefferies
-
United Therapeutics Corp. (UTHR) PT Raised to $615 at Leerink Partners
-
H.C. Wainwrigh on United Therapeutics Corp. (UTHR): 'We believe ralinepag is a win mechanistically and clinically'
-
United Therapeutics ralinepag shows 55% risk reduction in PAH study
-
United Therapeutics Corp. (UTHR) PT Raised to $600 at H.C. Wainwright
-
United Therapeutics Corp. (UTHR) PT Raised to $575 at TD Cowen
-
United Therapeutics Corp. (UTHR) PT Raised to $569 at BofA Securities
-
United Therapeutics (UTHR) Tops Q4 EPS by 60c
-
UBS Reiterates Buy Rating on United Therapeutics Corp. (UTHR)
-
Increasing unusual option volume: PSQ UTHR OTLK IONS PTEN FEZ PEPG SLS LEG WSM UA BRKR EU ZSL ARMN PENG
-
TD Cowen on Biotechnology: '10+ Potential "Thome Run" Catalysts To Watch In 2026'
-
Jefferies Reiterates Buy Rating on United Therapeutics Corp. (UTHR)
-
BTIG on United Therapeutics Corp. (UTHR): 'we would love to see data post-launch on the cadence of adoption, both in PAH and PH-ILD'
-
United Therapeutics Corp. (UTHR) PT Raised to $575 at Jefferies
-
United Therapeutics Corp. (UTHR) PT Raised to $525 at TD Cowen
-
United Therapeutics (UTHR) PT Raised to $447 at Morgan Stanley
-
United Therapeutics (UTHR) Misses Q3 EPS by 16c
-
TD Cowen on United Therapeutics Corp. (UTHR): 'Survey Highlight Significant IPF Tyvaso Opportunity'
-
Jefferies on United Therapeutics Corp. (UTHR): 'we don't think the new order/ responses change our view on trial outcomes'
-
UBS Reiterates Buy Rating on United Therapeutics Corp. (UTHR)
-
H.C. Wainwright Reiterates Buy Rating on United Therapeutics Corp. (UTHR)
-
United Therapeutics Corp. (UTHR) PT Raised to $580 at UBS
-
TD Cowen Reiterates Buy Rating on United Therapeutics Corp. (UTHR)
-
RBC Capital Starts United Therapeutics Corp. (UTHR) at Outperform
-
United Therapeutics Corp. (UTHR) Stock Can 'Continue to Grind Higher' — UBS
-
United Therapeutics Corp. (UTHR) PT Raised to $525 at Cantor Fitzgerald
-
United Therapeutics Corp. (UTHR) PT Raised to $500 at H.C. Wainwright

